West Pharmaceutical Services Inc

West Pharmaceutical Services Inc(WST)股票分析

$384.020

+0.998 (+0.26%)收盘时

Loading chart…
最高
386.260
开盘
382.740
成交量加权均价
383.52
成交量
511.19K
市值
23.95B
最低
380.280
成交额
196.05M
企业价值/息税折旧摊销前利润(TTM)
26.59

West Pharmaceutical Services Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its segments include Proprietary Products and West Vantage. Its Proprietary Products segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily for biologic, generic and pharmaceutical drug customers. Its West Vantage segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, as well as combination product assembly and packaging, primarily for pharmaceutical, diagnostic, and medical device customers. It also maintains collaborations to share technologies and market products with affiliates in Japan and Mexico. Its customers include generic, pharmaceutical, diagnostic, and medical device companies.

AI 分析 of West Pharmaceutical Services Inc (WST)

买入

West Pharmaceutical Services Inc is a good buy right now, trading at $366 with a forward P/E of 37.45, indicating strong growth potential. The company has shown a 39.44% increase over the past year and a 5.71% increase over the last 20 days, suggesting a positive momentum. Additionally, hedge funds have increased their buying activity by 196.32% over the last quarter, reflecting strong institutional confidence. However, the main risk is the RSI at 46.01, indicating that the stock is approaching oversold territory, which could lead to short-term volatility.

分析师评级(7)

-9.20% 下跌空间
买入
4 买入
2 持有
1 卖出
当前: 384.02
最低
285.00
平均
348.70
最高
375.00

Barclays

2026-10-07

目标价

$440

增持

Morgan Stanley

2026-09-22

目标价

$400

增持

UBS

2026-09-09

目标价

$415

买入

Citi

2026-08-03

目标价

$412

买入

Evercore ISI

2026-07-27

目标价

$425

跑赢大盘

估值指标

West Pharmaceutical Services Inc(WST)当前预期市盈率为 37.04,5 年平均预期市盈率为 41.22。

预期市盈率

合理
5 年均值 P/E
41.22
当前P/E
37.04
高估
48.02
低估
34.42

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
26.84
当前EV/EBITDA
26.59
高估
31.76
低估
21.92

预期市销率

合理
5 年均值 P/S
7.51
当前P/S
7.35
高估
9.10
低估
5.93

Alphio AI 对 WST 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%WST

$201.68

情景价格

基

基准

基准 · 50%WST

$194.98

情景价格

悲

悲观

悲观 · 25%WST

$174.26

情景价格

持有 WST 的大户

G

Generation Investment Management LLP

+ 持有WST

+10.11%

3个月收益率

N

Nan Shan Life Insurance Co., Ltd.

+ 持有WST

+7.50%

3个月收益率

W

Walter Scott & Partners Limited

+ 持有WST

+6.20%

3个月收益率

C

Curi Capital, LLC

+ 持有WST

+5.77%

3个月收益率

L

LGT Capital Partners Ltd.

+ 持有WST

+4.08%

3个月收益率

R

Riverbridge Partners, LLC

+ 持有WST

+4.04%

3个月收益率

WST 常见问题 —— 由 Alphio AI 解答

West Pharmaceutical Services Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its segments include Proprietary Products and West Vantage. Its Proprietary Products segment offers proprietary packaging, containment solutions and drug delivery systems, along with analytical lab services and other integrated services and solutions, primarily for biologic, generic and pharmaceutical drug customers. Its West Vantage segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, as well as combination product assembly and packaging, primarily for pharmaceutical, diagnostic, and medical device customers. It also maintains collaborations to share technologies and market products with affiliates in Japan and Mexico. Its customers include generic, pharmaceutical, diagnostic, and medical device companies. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

West Pharmaceutical Services Inc is a good buy right now, trading at $366 with a forward P/E of 37.45, indicating strong growth potential. The company has shown a 39.44% increase over the past year and a 5.71% increase over the last 20 days, suggesting a positive momentum. Additionally, hedge funds have increased their buying activity by 196.32% over the last quarter, reflecting strong institutional confidence. However, the main risk is the RSI at 46.01, indicating that the stock is approaching oversold territory, which could lead to short-term volatility.

7 analysts cover WST: 4 rate it Buy, 2 Hold and 1 Sell. The average price target is 348.70.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易